Home    Back

Cap-1002    (DrugBank: CAP-1002)

1 disease
IDDisease name (Link within this page)Number of trials
113Muscular dystrophy3

113. Muscular dystrophy    [ 567 clinical trials,   442 drugs,   (DrugBank: 93 drugs),   55 drug target genes,   151 drug target pathways]
Searched query = "Muscular dystrophy", "Dystrophinopathies", "Myotilinopathy", "Laminopathy", "Caveolinopathy", "LGMD1C", "Desminopathy", "Sarcoglycanopathy", "α-dystroglycanopathy", "FCMD", "Walker-Warburg syndrome", "Muscle-eye-brain disease", "Myotonic dystrophy", "Integrin α7 deficient CMD", "Rigid spine syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 567 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04428476
(ClinicalTrials.gov)		July 20, 20209/6/2020Open-label Extension of the HOPE-2 TrialOpen-Label Extension of the HOPE-2 Duchenne Muscular Dystrophy TrialDuchenne Muscular DystrophyBiological: CAP-1002Capricor Inc.NULLEnrolling by invitation10 YearsN/AAll14Phase 2United States
2NCT03406780
(ClinicalTrials.gov)		March 4, 201815/1/2018A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular DystrophyA Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Intravenous Delivery of Allogeneic Cardiosphere-Derived Cells in Subjects With Duchenne Muscular DystrophyMuscular Dystrophies;Muscular Dystrophy, Duchenne;Muscular Disorders, Atrophic;Muscular Diseases;Neuromuscular Diseases;Nervous System Diseases;Genetic Diseases, X-Linked;Genetic Diseases, InbornBiological: CAP-1002;Drug: PlaceboCapricor Inc.NULLCompleted10 YearsN/AMale18Phase 2United States
3NCT02485938
(ClinicalTrials.gov)		January 201619/6/2015HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne)A Randomized, Open-label Study of the Safety and Efficacy of Multi- Vessel Intracoronary Delivery of Allogeneic Cardiosphere-Derived Cells in Patients With Cardiomyopathy Secondary to Duchenne Muscular DystrophyDuchenne Muscular Dystrophy;CardiomyopathyDrug: Allogeneic Cardiosphere-Derived Cells (CAP-1002)Capricor Inc.NULLCompleted12 YearsN/AMale25Phase 1;Phase 2United States